<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33746">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02667288</url>
  </required_header>
  <id_info>
    <org_study_id>A-101-SEBK-303</org_study_id>
    <nct_id>NCT02667288</nct_id>
  </id_info>
  <brief_title>An Open-Label Safety Study of A-101 Solution</brief_title>
  <official_title>An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aclaris Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aclaris Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label safety study. During this study, the investigator will identify 4
      eligible SK Target Lesions on each subject on the trunk, extremities and face.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label safety study. During this study, the investigator will identify 4
      eligible SK Target Lesions on each subject on the trunk, extremities and face. The Target
      Lesions will be treated a maximum of 4 times.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of lesions clear Scale</measure>
    <time_frame>Study day 148</time_frame>
    <description>Scale</description>
  </primary_outcome>
  <other_outcome>
    <measure>Lesion Clearance Scale</measure>
    <time_frame>Day 148</time_frame>
    <description>Scale</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Seborrheic Keratosis</condition>
  <arm_group>
    <arm_group_label>A-101 Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-101 Solution 40% administered once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A-101 Solution</intervention_name>
    <arm_group_label>A-101 Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is at least 18 years of age

          2. Clinical diagnosis of stable clinically typical seborrheic keratosis

          3. Subject has 4 appropriate seborrheic keratosis Target Lesions on the trunk,
             extremities and face that each are eligible for treatment as defined below:

               -  Have a clinically typical appearance

               -  Have a PLA of 2 or greater and be a discrete lesion

               -  Not be covered with hair which, in the investigator's opinion, would interfere
                  with the study medication treatment or the study evaluations

               -  Not be in an intertriginous fold

               -  Not be on the eyelids

               -  Not be within 5mm of the orbital rim

               -  Not be pedunculated

          4. If the subject is a woman of childbearing potential, she has a negative urine
             pregnancy test and agrees to use an active method of birth control for the duration
             of the study

          5. Subject is non-pregnant and non-lactating

          6. Subject is in good general health and free of any known disease state or physical
             condition which, in the investigator's opinion, might impair evaluation of any Target
             Lesion or which exposes the subject to an unacceptable risk by study participation

          7. Subject is willing and able to follow all study instructions and to attend all study
             visits

          8. Subject is able to comprehend and willing to sign an Informed Consent Form.

        Exclusion Criteria:

          1. Subject has clinically atypical and - or rapidly growing seborrheic keratosis lesions

          2. Subject has presence of multiple eruptive seborrheic keratosis lesions (Sign of
             Lesser -Trelat)

          3. Subject has a current systemic malignancy

          4. Subject has used any of the following systemic therapies within the specified period
             prior to enrollment:

               -  Retinoids; 180 days

               -  Glucocortico-steroids;

               -  Anti-metabolites (e.g., methotrexate);

          5. Subject has used any of the following topical therapies within the specified period
             or in a proximity to any Target Lesion, that in the investigator's opinion interferes
             with the study medication treatment or the study assessments:

               -  LASER, light or other energy based therapy (e.g., intense pulsed light,
                  photo-dynamic therapy;

               -  Liquid nitrogen, electrodesiccation, curettage, imiquimod, 5-flurouracil, or
                  ingenol mebutate;

               -  Retinoids;

               -  Microdermabrasion or superficial chemical peels;

               -  Glucocortico-steroids or antibiotics

          6. Subject currently has or has had any of the following within the specified period or
             in a proximity to any Target Lesion that, in the investigator's opinion, interferes
             with the study medication treatment or the study assessments:

               -  A cutaneous malignancy;

               -  A sunburn; currently

               -  A pre-malignancy (e.g., actinic keratosis); currently

               -  Body art (e.g., tattoos, piercing, etc.); currently

               -  Excessive tan; currently

          7. Subject has a history of sensitivity to any of the ingredients in the study
             medications

          8. Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun
             damage, etc.), or condition (e.g., sunburn, excessive hair, open wounds) that, in the
             opinion of the investigator, might put the subject at undue risk by study
             participation or interfere with the study conduct or evaluations

          9. Subject has participated in an investigational drug trial in which administration of
             an investigational study medication occurred within 30 days prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart D Shanler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aclaris Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aclaris Therapeutics, Inc.</name>
      <address>
        <city>Malvern</city>
        <state>Pennsylvania</state>
        <zip>19355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 1, 2016</lastchanged_date>
  <firstreceived_date>January 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis, Seborrheic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
